论文部分内容阅读
目的观察胺碘酮在重度左心衰竭(SLHF)合并心房颤动(房颤)治疗中的临床疗效与安全性。方法 100例SLHF合并房颤(AF)患者,采用便利抽样法分为对照组与观察组,各50例。对照组采用普罗帕酮治疗,观察组采用普罗帕酮联合胺碘酮治疗,对比两组的临床疗效与用药安全性。结果治疗后,两组的血压与心率均较治疗前有所改善,观察组较对照组改善程度更为明显,差异具有统计学意义(P<0.05)。观察组显效17例、有效28例、无效5例,总有效率为90%;对照组显效10例、有效27例、无效13例,总有效率为74%,观察组总有效率明显高于对照组,差异具有统计学意义(P<0.05)。观察组治疗期间不良反应发生率为10%,对照组不良反应发生率为14%,两组比较差异无统计学意义(P>0.05)。结论胺碘酮与普罗帕酮联用可以明显改善SLHF合并AF患者的临床症状,疗效确切,安全性高。
Objective To observe the clinical efficacy and safety of amiodarone in the treatment of severe left ventricular failure (SLHF) complicated with atrial fibrillation (AF). Methods 100 patients with SLHF complicated with atrial fibrillation (AF) were divided into control group and observation group by using convenience sampling method, each 50 cases. The control group was treated with propafenone, the observation group was treated with propafenone combined with amiodarone, the clinical efficacy and safety of the two groups were compared. Results After treatment, the blood pressure and heart rate of both groups were improved compared with those before treatment. The improvement degree of the observation group was more obvious than that of the control group, the difference was statistically significant (P <0.05). In the observation group, 17 cases were markedly effective, 28 cases were effective, 5 cases were ineffective, and the total effective rate was 90%. In the control group, 10 cases were markedly effective, 27 cases were effective and 13 cases were ineffective. The total effective rate was 74% Control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group during treatment was 10%, while the incidence of adverse reactions in the control group was 14%. There was no significant difference between the two groups (P> 0.05). Conclusions Combined use of amiodarone and propafenone can significantly improve the clinical symptoms of SLHF patients with AF, with definite curative effect and high safety.